Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

References

• World Health Organization. WHO coronavirus (COVID-19) dashboard; 2022. [cited 13 Nov 2022]. https://covid19.who.int/
   Google Scholar
• Institute for Health Metrics and Evaluation. IHME COVID-19 projections; 2022. [cited 13 Nov 2022]. https://covid19.healthdata.org/global?view=cumulative-deaths&tab=trend
   Google Scholar
• Collaborators C-E, Paulson KR, Pease SA. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet. 2022;399(10334):1513–1536.
   PubMed Web of Science ®Google Scholar
• Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293–1302.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. Novavax COVID-19 vaccine, adjuvanted; 2022. [cited 15 Nov 2022]. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted
   Google Scholar
• U.S. Food & Drug Administration. Moderna COVID-19 vaccines; 2021. [cited 15 Nov 2022]. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines
   Google Scholar
• U.S. Food & Drug Administration. Pfizer-BioNTech COVID-19 vaccines; 2021. [cited 15 Nov 2022]. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines
   Google Scholar
• U.S. Food & Drug Administration. Janssen COVID-19 vaccine; 2021. [cited 15 Nov 2022]. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine
   Google Scholar
• VIPER Group COVID 19 Vaccine Tracker Team. COVID-19 Vaccine Tracker: Vaccines granted emergency use listing by WHO; 2022. [cited 13 Nov 2022]. https://covid19.trackvaccines.org/agency/who/
   Google Scholar
• Cid R, Bolivar J. Platforms for production of protein-based vaccines: from classical to next-generation strategies. Biomolecules. 2021;11(8). DOI:10.3390/biom11081072
   Web of Science ®Google Scholar
• Marchese AM, Beyhaghi H, Orenstein WA. With established safe and effective use, protein vaccines offer another choice against COVID-19. Vaccine. 2022;40(46):6567–6569.
   PubMed Web of Science ®Google Scholar
• Tian JH, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12(1):372. DOI:10.1038/s41467-020-20653-8
   PubMed Web of Science ®Google Scholar
• Stertman L, Palm A-K, Zarnegar B, et al. The Matrix-M™ adjuvant: a critical component of vaccines for the 21st century. Hum Vaccin Immunother. 2023;2023(1):2189885. DOI:10.1080/21645515.2023.2189885
   Google Scholar
• Bengtsson KL, Song H, Stertman L, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine. 2016;34(16):1927–1935. DOI:10.1016/j.vaccine.2016.02.033
   PubMed Web of Science ®Google Scholar
• Lovgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011;10(4):401–403.
   PubMed Web of Science ®Google Scholar
• Magnusson SE, Altenburg AF, Bengtsson KL, et al. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66(2):224–233. DOI:10.1007/s12026-018-8991-x
   PubMed Web of Science ®Google Scholar
• Martín RS, Briones R. Industrial uses and sustainable supply of Quillaja saponaria (Rosaceae) saponins. Econ Bot. 1999;53(3):302–311.
   Web of Science ®Google Scholar
• Pulendran B, SA P, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–475.
   PubMed Web of Science ®Google Scholar
• Kensil CR, Patel U, Lennick M, et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol. 1991;146(2):431–437.
   PubMed Web of Science ®Google Scholar
• Waite DC, Jacobson EW, Ennis FA, et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine. 2001;19(28):3957–3967. DOI:10.1016/S0264-410X(01)00142-6
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Laupèze B, Di Pasquale A, et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16(1):55–63.
   PubMed Web of Science ®Google Scholar
• Morein B, Sundquist B, Höglund S, et al. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984;308(5958):457–460.
   PubMed Web of Science ®Google Scholar
• Drane D, Gittleson C, Boyle J, et al. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines. 2007;6(5):761–772.
   PubMed Web of Science ®Google Scholar
• Garcia A, Lema D. An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines. Curr Pharm Des. 2016;22(41):6294–6299.
   PubMed Web of Science ®Google Scholar
• Fossum C, Hjertner B, Ahlberg V, et al. Early inflammatory response to the saponin adjuvant Matrix-M in the pig. Vet Immunol Immunopathol. 2014;158(1–2):53–61. DOI:10.1016/j.vetimm.2013.07.007
   PubMed Web of Science ®Google Scholar
• Datoo MS, Natama MH, Some A, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021;397(10287):1809–1818. DOI:10.1016/S0140-6736(21)00943-0
   PubMed Web of Science ®Google Scholar
• Shinde V, Cho I, Plested JS, et al. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. Lancet Infect Dis. 2022;22(1):73–84. DOI:10.1016/S1473-3099(21)00192-4
   PubMed Web of Science ®Google Scholar
• Fries L, Cho I, Krahling V, et al. Randomized, blinded, dose-ranging trial of an ebola virus glycoprotein nanoparticle vaccine with Matrix-M adjuvant in healthy adults. J Infect Dis. 2020;222(4):572–582. DOI:10.1093/infdis/jiz518
   PubMed Web of Science ®Google Scholar
• Madhun AS, Haaheim LR, Nilsen MV, et al. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine. 2009;27(52):7367–7376.
   PubMed Web of Science ®Google Scholar
• Pedersen GK, Sjursen H, Nostbakken JK, et al. Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. Hum Vaccin Immunother. 2014;10(8):2408–2416.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320–2332. DOI:10.1056/NEJMoa2026920
   PubMed Web of Science ®Google Scholar
• Formica N, Mallory R, Albert G, et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Med. 2021;18(10):e1003769. DOI:10.1371/journal.pmed.1003769
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. Development and licensure of vaccines to prevent COVID-19, guidance for industry. [cited 15 Nov 2022]. https://www.fda.gov/media/139638/download.
   Google Scholar
• Rydyznski Moderbacher C, Kim C, Mateus J, et al. NVX-Cov2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses. J Clin Invest. 2022;132(19):e160898.
   PubMed Web of Science ®Google Scholar
• Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022;185(5):847–859 e811. DOI:10.1016/j.cell.2022.01.015
   PubMed Web of Science ®Google Scholar
• Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2022;22(11):1565–1576. DOI:10.1016/S1473-3099(22)00420-0
   PubMed Web of Science ®Google Scholar
• Madhi SA, Moodley D, Hanley S, et al. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. Lancet HIV. 2022;9(5):e309–e322. DOI:10.1016/S2352-3018(22)00041-8
   PubMed Web of Science ®Google Scholar
• Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N Engl J Med. 2021;385(13):1172–1183. DOI:10.1056/NEJMoa2107659
   PubMed Web of Science ®Google Scholar
• Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of the NVX-CoV2373 COVID-19 vaccine at completion of the placebo-controlled phase of a randomized controlled trial. Clin Infect Dis. 2022;76(3):398–407.
   Web of Science ®Google Scholar
• Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386(6):531–543. DOI:10.1056/NEJMoa2116185
   PubMed Web of Science ®Google Scholar
• Toback S, Galiza E, Cosgrove C, et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Resp Med. 2022;10(2):167–179. DOI:10.1016/S2213-2600(21)00409-4
   PubMed Web of Science ®Google Scholar
• Áñez G, Dunkle LM, Gay CL, et al. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: a Randomized Clinical Trial. JAMA Netw Open. 2023;6(4):e239135–e239135. DOI:10.1001/jamanetworkopen.2023.9135
   PubMed Web of Science ®Google Scholar
• Alves K, Plested JS, Glabiati S, et al. Immunogenicity and safety of a 4th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial. medRxiv. 2022:2022.11.18.22282414.
   PubMedGoogle Scholar
• Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899–1909. DOI:10.1056/NEJMoa2103055
   PubMed Web of Science ®Google Scholar
• Marchese AM, Zhou X, Kinol J, et al. NVX-Cov2373 Vaccine Efficacy Against Hospitalization: a post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial. medRxiv. 2023:2023.03.17.23287306.
   PubMedGoogle Scholar
• World Health Organization. Tracking SARS-CoV-2 variants. [cited 15 Nov 2022]. https://www.who.int/activities/tracking-SARS-CoV-2-variants.
   Google Scholar
• Alves K, Plested JS, Galbiati S, et al. Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373. N Engl J Med. 2023;388(9):857–859. DOI:10.1056/NEJMc2215509
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EMA recommends authorisation of Nuvaxovid for adolescents aged 12 to 17; 2022. [cited 15 Nov 2022]. https://www.ema.europa.eu/en/news/ema-recommends-authorisation-nuvaxovid-adolescents-aged-12-17
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. DOI:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416. DOI:10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira ED Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761–1773. DOI:10.1056/NEJMoa2110345
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. DOI:10.1056/NEJMoa2101544
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med. 2022;386(9):847–860. DOI:10.1056/NEJMoa2117608
   PubMed Web of Science ®Google Scholar
• Patone M, Mei XW, Handunnetthi L, et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation. 2022;146(10):743–754. DOI:10.1161/CIRCULATIONAHA.122.059970
   PubMed Web of Science ®Google Scholar
• Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28(2):410–422. DOI:10.1038/s41591-021-01630-0
   PubMed Web of Science ®Google Scholar
• Witberg G, Barda N, Hoss S, et al. Myocarditis after COVID-19 vaccination in a large health care organization. N Engl J Med. 2021;385(23):2132–2139. DOI:10.1056/NEJMoa2110737
   PubMed Web of Science ®Google Scholar
• Kornowski R, Witberg G. Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination. Open Heart. 2022;9(1). DOI:10.1136/openhrt-2021-001957
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. Coronavirus (COVID-19) update: fDA limits use of Janssen COVID-19 vaccine to certain individuals. [cited 15 Nov 2022]. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals#:~:text=Today%2C%20the%20U.S.%20Food%20and,who%20elect%20to%20receive%20the.
   Google Scholar
• Centers for Disease Control and Prevention. Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults; 2022. [cited 15 Nov 2022]. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html
   Google Scholar
• European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC); 29 Nov, 2 Dec 2021. [cited 15 Nov 2022]. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-29-november-2-december-2021
   Google Scholar
• World Health Organization. Strategy to achieve global COVID-19 vaccination by mid-2022. [cited 13 Nov 2022]. https://cdn.who.int/media/docs/default-source/immunization/covid-19/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022.pdf.
   Google Scholar
• Our World in Data. Coronavirus (COVID-19) vaccinations. [cited 15 Nov 2022]. https://ourworldindata.org/covid-vaccinations.
   Google Scholar
• Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. [cited 15 Nov 2022]. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-fully-percent-pop5.
   Google Scholar
• Thunstrom L, Ashworth M, Finnoff D, et al. Hesitancy toward a COVID-19 vaccine. Ecohealth. 2021;18(1):44–60.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Novavax COVID-19 Vaccine Storage and Handling Summary. [cited 18 Dec 2022]. https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-storage-handling-summary.pdf.
   Google Scholar
• Bhiman JN, Richardson SI, Lambson BE, et al. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. Sci Rep. 2023;13(1):1222. DOI:10.1038/s41598-023-27698-x
   PubMed Web of Science ®Google Scholar